CAS 2049980-18-7

Formula: C25H29N7O4S

InChI: InChI=1S/C25H29N7O4S/c1-15-10-19(14-26-11-15)24-29-30-25(32(24)22-20(35-5)8-7-9-21(22)36-6)31-37(33,34)18(4)17(3)23-27-12-16(2)13-28-23/h7-14,17-18H,1-6H3,(H,30,31)/t17-,18-/m0/s1

InChI key: DOMQFIFVDIAOOT-ROUUACIJSA-N

SMILES: CC1=CC(=CN=C1)C2=NN=C(N2C3=C(C=CC=C3OC)OC)NS(=O)(=O)[C@@H](C)[C@H](C)C4=NC=C(C=N4)C

Azelaprag

CAS: 2049980-18-7

Azelaprag

Formula: C₂₅H₂₉N₇O₄S

Purity: ≥95%

Molecular weight: 523.61

Ref: 54-BUP09015

(2S,3R)-N-(4-(2,6-Dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide

CAS: 2049980-18-7

Formula: C₂₅H₂₉N₇O₄S

Purity: 99%

Color and Shape: Solid

Molecular weight: 523.6073

Ref: IN-DA020198

Azelaprag

CAS: 2049980-18-7

(2S,3R)-N-(4-(2,6-Dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-4H-1,2,4-triazol-3-yl)-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide

Formula: C₂₅H₂₉N₇O₄S

Purity: 99% 95%ee

Molecular weight: 523.61

Ref: IN-DG01139364

Azelaprag

CAS: 2049980-18-7

Azelaprag is a prodrug of saquinavir that has been shown to be effective in the prevention and treatment of pyloric stenosis. It is administered orally and can be detected in the blood, nasal secretions, or urine. Azelaprag is also active against Staphylococcus and Streptococcus isolates, but not against other bacteria. Azelaprag has been shown to produce drug reactions in women and infants, with detectable levels in the blood or urine.

Formula: C₂₅H₂₉N₇O₄S

Purity: Min. 95%

Molecular weight: 523.6 g/mol

Ref: 3D-ZGD98018

Azelaprag

CAS: 2049980-18-7

Azelaprag (Example 263.0) is a candidate active molecule (EC50= 0.32 nM) for an apelin receptor agonist. treat nervous system diseases. High-Quality, Low-Cost!

Formula: C₂₅H₂₉N₇O₄S

Purity: 98.04% - >99.99%

Color and Shape: Solid

Molecular weight: 523.61

Ref: TM-T14390